IQ Therapeutics has developed a proprietary technology for the generation of fully human antibodies from the blood of vaccinated or immunized donors. It is our philosophy that the most physiological origin for antibodies to be applied as therapeutic agent inside a human body is the human body itself. The human immune response is the basis for our technology and therefore we have termed it "Cloning
the Human ResponseTM". Our aim is to apply this technology for the generation of protective antibodies which can serve as passive immunization to protect humans against infectious diseases and biodefense, thus providing "instant immunity". For Anthrax infections we have developed human monoclonal antibodies directed against two components of the lethal toxin, PA and LF. IQ has taken its unique anti-LF antibody as its lead product for drug development towards registration. "Cloning the Human ResponseTM" is also applied for various in-house developments to build a pipeline of potential novel antibody based drugs. Moreover, we offer the technology as service for third parties.
